Ryvu Therapeutics SA · GPW:RVU
Ryvu Therapeutics SA — Investor Presentation (May 2025)
50 slides from Ryvu Therapeutics SA's investor presentation, May 7, 2025

Slide 1: Corporate Presentation
Developing therapeutics at the forefront of oncology Corporate Presentation May 7, 2025

Slide 2: Note on the presentation and forward-looking statements
Note on the presentation and forward-looking statements This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, or any other offer or invitation to acquire any Company's securities, nor the incentive to subm

Slide 3: Ryvu is developing novel therapies to address high-value emerging targets in oncology
Ryvu is developing novel therapies to address high-value emerging targets in oncology Clinical and Prelinical Candidate Pipeline Novel Multi-Target Discovery RVU120 • First-in-class, oral CDK8/19 inhibitor • Four Ph II studies ongoing: mono and combo in ONCO Prime Platform • Multiple novel precisi

Slide 4: Team with a strong track record of clinical development and shareholder value creation
Team with a strong track record of clinical development and shareholder value creation Pawel Przewięźlikowski, MSc, MBA Krzysztof Brzózka, PhD, MBA Hendrik Nogai, MD Kamil Sitarz, PhD, MBA CEO and Founder CSO CMO COO Vatnak Vat-Ho, MBA Jakub Janowski, MSc Justyna Żółtek, MSc Bartłomiej Konicki, MSc

Slide 5: Broad pipeline addressing emerging targets in oncology
Broad pipeline addressing emerging targets in oncology EXPECTED PROGRAM INDICATION DISCOVERY PRECLINICAL PHASE I PHASE II PARTNER MILESTONES R/R AML Updated Ph II data RIVER-81 (combo with venetoclax) in 2Q25 Q R/R AML/HR-MDS RIVER-52 Updated Ph II data (monotherapy) (enrollment suspended) in 2Q25 R

Slide 6: RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic Malignancies
RVU120: First-in-Class CDK8/19 Inhibitor in Hematologic Malignancies

Slide 7: RVU120 is a clinical-stage, first-in-class, small molecule CDK8/19 kinase inhibitor
RVU120 is a clinical-stage, first-in-class, small molecule CDK8/19 kinase inhibitor developed and fully-owned by Ryvu high selectivity 1 low risk of DDI (esp antifungals) easy to formulate orally bioavailable favorable safety profile RVU120 is an innovative dual CDK8/19 inhibitor designed to target

Slide 8: RVU120: opportunities across a broad range of cancers
RVU120: opportunities across a broad range of cancers Blood Cancers & Disorders Solid Tumors Medulloblastoma AML Low-risk MDS ACC Myelofibrosis (MF) Breast High-risk MDS MDS/MPN overlap syndrome Sarcoma NHL Diamond-Blackfan Anemia • Signs of clinical activity in AML ▪ Translational evidence in multi

Slide 9: RVU120 Diversified clinical program with high commercial potential
RVU120 Diversified clinical program with high commercial potential 2024 2025 2026 2027 2028 Beyond 2028 I II III IV I II III IV I II III IV I II III IV I II III IV Phase II studies in hematologic malignancies • RIVER-81: AML, combination with venetoclax Ph II Part 1 Ph II Parts 2 and 3 Phase III (po

Slide 10: RVU120 Phase II development plan rationale: RIVER-51 clinical data
RVU120 Phase II development plan rationale: RIVER-51 clinical data 15 of 30 evaluable patients showed clinical benefit across dose levels Clinical benefits • 30 treated patients are evaluable for response (38 were treated in total) • 9 patients achieved clinically significant BM blast reduction • (i

Slide 11: Data generated in RIVER-51 study support further development of RVU120
Data generated in RIVER-51 study support further development of RVU120 in AML, LR-MDS and MF Significant blast reductions Transfusion independence Improvement of BM architecture • Confirmed CR in a patient with AML • >20% patients, (all with AML-MR or HR-MDS), • Signs of activity in secondary AML •

Slide 12: RIVER-81 in ven-refractory patients with AML
Phase II study testing RVU120 in combination with venetoclax RIVER-81 in ven-refractory patients with AML STUDY DESIGN • Primary endpoints: ― Rate of CR, CRh, CRi, with and without MRD, and DoR • Secondary endpoints: Transfusion independence, PFS, RFS, OS RVU120 + • For Part 2: including PRO and HRQ

Slide 13: RIVER-81 Strong nonclinical evidence for synergy between RVU120 and venetoclax
RIVER-81 Strong nonclinical evidence for synergy between RVU120 and venetoclax providing rationale for a Phase II study in venetoclax refractory patients MV4-11 • True Synergy and Superiority: RVU120 + VEN • RVU120 + ven demonstrates synergy across multiple AML cell lines and superiority over ven +

Slide 14: RIVER-81 Part 1 (dose escalation) has been completed; Part 2 is enrolling
RIVER-81 Part 1 (dose escalation) has been completed; Part 2 is enrolling STUDY PLAN PART 1 PART 2: Simon 2-stage design PART 3: Confirmatory Stage 1 Stage 2 Confirmatory cohort Cohort 1 Cohort 2 Cohort 3 RVU120 125 mg RVU120 250 mg RVU120 250 mg RVU120 250 mg + N≤18 RVU120 same dose N≤11 Same dose

Slide 15: RIVER-81 One patient achieved a CR in a difficult to treat ven-refractory population
RIVER-81 One patient achieved a CR in a difficult to treat ven-refractory population Decrease of bone marrow blasts from 20% to 9% in flow cytometry on C2D13 Cytomorphological decrease of bone marrow blasts to < 5% on C1D13 Next data update in June 2025 Data Cut-off: December 10, 2024 Preliminary da

Slide 16: POTAMI-61 Phase II study of RVU120 in myelofibrosis as mono and combo
POTAMI-61 Phase II study of RVU120 in myelofibrosis (MF) as mono and combo – first patient was dosed in December 2024 STUDY DESIGN • Population: • Primary or secondary MF; intermediate or high-risk MF per DIPSS; Cohort 1) previously treated with or ineligible for JAK inhibitor and Cohort 2) suboptim

Slide 17: POTAMI-61 RVU120 validated preclinically as a drug candidate in MF
POTAMI-61 RVU120 validated preclinically as a drug candidate in MF Mechanism of RVU120 RVU120 reduces Opportunity in myelofibrosis in MF splenomegaly RVU120 as a monotherapy and in combination • Growing market with many patients undiagnosed or not treated with ruxolitinib reduces splenomegaly due to

Slide 18: REMARK and the EMSCO network
RVU120 in LR-MDS – IIT conducted by Prof. Uwe Platzbecker REMARK and the EMSCO network PHASE II STUDY DESIGN • Population: EXPLORATORY • Patients with relapsed/refractory LR-MDS RVU120 AS A SINGLE AGENT • Primary endpoint: • Erythroid response (HI-E) according to IWG 2018 criteria after 8 cycles of

Slide 19: REMARK RVU120 validated preclinically as a drug candidate in LR-MDS
REMARK RVU120 validated preclinically as a drug candidate in LR-MDS Opportunity in LR-MDS Mechanism of RVU120 in LR-MDS • A high unmet medical need remains in low-risk MDS (LR-MDS) after failure of available therapies • Transfusion burden remains high for patients with LR-MDS, resulting a poor quali

Slide 20: REMARK RVU120 has strong erythroid-stimulating activity in nonclinical anemia models
REMARK RVU120 has strong erythroid-stimulating activity in nonclinical anemia models and selected patients with AML/HR-MDS in Phase I (RIVER-51), providing the rationale for the Phase II clinical study in patients with LR-MDS Nonclinical rationale • Treatment of transformed CD34+ cells with RVU120 r

Slide 21: RIVER-52 Phase II study with RVU120 as a single agent in AML/HR-MDS
RIVER-52 Phase II study with RVU120 as a single agent in AML/HR-MDS STUDY DESIGN • Primary endpoints: ― Rate of CR, CRh, CRi, with and without MRD, and DoR RVU120 • Secondary endpoints: ― Transfusion independence, Progression-free survival, Relapse-free survival (RFS), Overall survival monotherapy •

Slide 22: RVU120 Phase II clinical development with a global footprint
RVU120 Phase II clinical development with a global footprint Global site locations and patient population Global CROs and clinical vendors Planned locations for RVU120 Ph II studies: Part 1: exploratory data Regulatory authorities Part 2: expansion worldwide Status as of February 24, 2025 Number of

Slide 23: RVU120 Market potential in hematological malignancies
RVU120 Market potential in hematological malignancies AML (Acute Myeloid Leukemia) MDS (Myelodysplastic Syndrome) MF (Myelofibrosis) • The most common, highly aggressive type • Disease leading to bone marrow damage, • MF is a bone marrow disease characterized of acute leukemia occurring in adults; c

Slide 24: Program on track with next efficacy readouts in June 2025
Program on track with next efficacy readouts in June 2025 RVU120 Approx. 120 patients have already been dosed across all RVU120 Phase II studies (as of Feb. 24, 2025) RVU120 program summary • Accelerating enrollment across Phase II program RIVER-81 Next data in June 2025 o 3 Phase II studies in prog

Slide 25: Dapolsertib (MEN1703, SEL24) First-in-Class PIM/FLT3 Inhibitor
Dapolsertib (MEN1703, SEL24) First-in-Class PIM/FLT3 Inhibitor

Slide 26: Dapolsertib JASPIS-01 Phase II clinical study in DLBCL
Dapolsertib (MEN1703, SEL24) JASPIS-01 Phase II clinical study in DLBCL DLBCL PARTNERSHIP AGREEMENT PROVEN SAFETY WITH MENARINI GROUP AND CLINICAL ACTIVITY • Development continues with the initiation of a new Phase II study in relapsed/refractory diffuse large B-cell (2017) lymphoma (DLBCL) Future O

Slide 27: Phase II in DLBCL
Phase II in DLBCL DAPOLSERTIB PROFILE • First-in-class dual PIM/FLT3 inhibitor with a unique mechanism of action • Differentiated activity in cellular models compared to selective PIM inhibitors (broader activity profile) CLINICAL STUDIES TO DATE • H1 2017- H1 2021 Phase I dose escalation and cohort

Slide 28: RVU305: MTA-cooperative PRMT5 inhibitor
RVU305: MTA-cooperative PRMT5 inhibitor • Best-in-class potency and selectivity • Brain-penetrant

Slide 29: RVU305: Best-in-class PRMT5 MTA-cooperative inhibitor in IND-enabling studies
RVU305: Best-in-class PRMT5 MTA-cooperative inhibitor in IND-enabling studies RVU305/PRMT5i RVU305 has best-in-class potential based on robust multiparameter optimization PRMT5 MTA-cooperative inhibitors • Antiproliferative activity: demonstrated in MTAP- KEY RATIONALE exert synthetic lethal phenot

Slide 30: RVU305 shows superiority in multiple cell lines
RVU305 shows superiority in multiple cell lines Analysis of pancreatic, lung and bladder cancer origin cell lines shows RVU305 superiority over MRTX1719 • Panel of MTAP-deleted and MTAP-wt cells was profiled with RVU305 in a 5-day CellTiter-Glo assay • A differential response to Ryvu PRMT5 MTA-coope

Slide 31: RVU305 shows significant antitumor efficacy in vivo
RVU305 shows significant antitumor efficacy in vivo Strong antitumor efficacy Complete responses demonstrated in vivo: favorable vs. MRTX1719 DoHH2 MTAP-deleted model (DLBCL) Tumor volume Tumor volume Tumor volume 4096 Individual tumor volume [mm3] 4096 RVU305, 150 mg/kg PO QD Individual tumor volum

Slide 32: RVU305 is CNS-penetrant PRMT5 inhibitor with predicted efficacious exposure in the brain
RVU305 is CNS-penetrant PRMT5 inhibitor with predicted efficacious exposure in the brain RVU305 shows optimal systemic target coverage and RVU305 exhibits high potency and efficacy excellent brain penetration against CNS cell lines Predicted free RVU305 exposure in projected human escalation phases

Slide 33: RVU305 has a potentially best-in-class profile
RVU305 has a potentially best-in-class profile • RVU305 is brain-penetrant and shows better target coverage in brain compared to AMG193 MRTX1719/ TNG462 TNG456 AMG193 RVU305 BMS-986504 • RVU305 has better selectivity Potency* +++ +++ ++ ++ +++ in MTAP-deleted vs WT cells compared to MRTX1719/ Brain

Slide 34: Early pipeline Dual-pronged strategy with potential to generate multiple oncology medicines
Early pipeline Dual-pronged strategy with potential to generate multiple oncology medicines Novel precision oncology Next-generation ONCO Prime ADCs drug discovery platform novel ADC payloads Broad potential to discover novel precision oncology targets, Potential to improve efficacy, safety and comb

Slide 35: ONCO Prime: Novel Precision Oncology
ONCO Prime: Novel Precision Oncology Multi-asset platform generating first-in-class therapeutics

Slide 36: Driving novel precision oncology drug discovery with Ryvu's ONCO Prime platform
Driving novel precision oncology drug discovery with Ryvu’s ONCO Prime platform Discovering Novel Precision Oncology Ryvu’s CRISPR-based target Discovery Platform Targets, including Synthetic Lethal Targets Engineered Model Patient-Derived Cells (PDCs) Synthetic Common Engineered Lethal APC KRAS TP5

Slide 37: Initial ONCO Prime data presented in CRC; broad applicability across oncology
Initial ONCO Prime data presented in CRC; broad applicability across oncology • The third most prevalent cancer worldwide • Estimated number of colorectal cancers in the US for 2024 are 153,000 new cases1 CRC • Diagnosed usually at an advanced stage. Mortality still remains high. Five-year survival

Slide 38: ONCO Prime is accelerating the development of novel precision medicine targets
ONCO Prime is accelerating the development of novel precision medicine targets, including synthetic lethal targets Modeling cancer progression High Throughput Screenings Novel Targets & Treatments APC KRAS TP53 SMAD4 Patient-derived material Ryvu’s OncoPrime platform has broad potential to discover

Slide 39: ADCs with Novel Payloads
ADCs with Novel Payloads Generating multiple first-in-class therapeutics

Slide 40: Novel payloads have the potential to improve efficacy and safety in next generation ADCs
Novel payloads have the potential to improve efficacy and safety in next generation ADCs Approved ADCs use three main types of payloads Novel payloads have the potential to improve on… Efficacy: overcome resistance to existing payloads and potentially improve on potency Safety: expand the safety win

Slide 41: ADCs Ryvu's payload strategy is focused on novel and potent mechanisms
ADCs Ryvu’s payload strategy is focused on novel and potent mechanisms PAYLOAD CLASSES IMMUNOMODULATORY SYNTHETICALLY LETHAL/ IMMUNOCYTOTOXIC POTENT CYTOTOXINS PAYLOADS PRECISION PAYLOADS PAYLOADS Traditional approach A newer approach Innovative approach Innovative approach Established cytotoxics •

Slide 42: Ryvu has shortlisted several immunocytotoxic payloads to advance
Ryvu has shortlisted several immunocytotoxic payloads to advance Based on initial screens at Ryvu, several targets have been selected as promising immunocytotoxic payloads. Some blinded examples are presented below. Low nM PoC as Single agent Pantoxic IO combo Target Drug name inhibitors ADC Type of

Slide 43: STING agonists licensed to Exelixis for ADCs
Ryvu has already developed a portfolio of immunostimulatory payloads: STING agonists licensed to Exelixis for ADCs 1 Building STING-based antibody drug conjugates (ADCs) 2 Leveraging Ryvu’s STING agonist portfolio and Exelixis’s ADC technology Partnership Key Financial Terms • Exclusive license agre

Slide 44: STING activating Antibody-Drug Conjugates
STING activating Antibody-Drug Conjugates STING activating Antibody-Drug Conjugates • Proprietary STING agonist chemotype • ADC development expertise • Localised immune response after systemic • Small-molecule, non-CDN structures • Antibodies against cancer-relevant administration antigens STING • I

Slide 45: BioNTech and Ryvu: global collaboration on immune modulation small molecules
BioNTech and Ryvu: global collaboration to develop and commercialize immune modulation small molecule candidates Largest-ever Ryvu deal: November 2022 Partnership Key Financial Terms • Multi-target research collaboration: Ryvu is conducting discovery • Ryvu received €40 million from BioNTech, and re

Slide 46: Corporate Progress
” ” cD) i= jee) fe) c= a. c)) ~ oO = fe] jos = °o O RYvU

Slide 47: Full-Year Financial Results: 2024
Full-Year Financial Results: 2024 € million 2023* 2024* Revenues 15.0 23.7 Cash position March 9, 2025 Partnering 10.5 18.1 Grants 4.5 5.6 €43.7M (PLN 182.3M) Total Costs** 34.7 51.0 In addition, the company has secured approximately Clinical Pipeline 12.0 25.7 €21.8M (PLN 91.0M) in non-dilutive gra

Slide 48: Ryvu's Vision remains unchanged: key goals and financing
Ryvu’s Vision remains unchanged: from 2026, Ryvu will improve the lives of cancer patients worldwide 2025 / KEY GOALS AND FINANCING RVU120 PROGRESS SUMMARY • RVU120 broad development • Accelerating enrollment across Phase II program (including potential fast-to-market strategy in AML/LR-MDS/MF) • Th

Slide 49: Ryvu equity summary
Ryvu equity summary Top Holders3 IPO on WSE Nov 2014 1 Paweł Przewięźlikowski 17.4% Corporate Split: Selvita and Ryvu Oct 2019 2 Allianz OFE 9.2% 3 BioNTech SE 8.3% Ticker: WSE RVU 4 Allianz TFI 6.9% 52-Week Range1 PLN 17.62 – 55.80 5 Nationale-Nederlanden OFE 6.0% Average Daily Volume (YTD) 1 63,74

Slide 50: Thank you
Thank you CONTACT DATA: Ryvu Therapeutics S.A. www.ryvu.com ryvu@ryvu.com ir@ryvu.com
Source: Internet Archive copy of ryvu.com
More decks from Ryvu Therapeutics SA
Investor Presentation (November 2026)41 slides · November 2026
Investor Presentation (September 2026)40 slides · September 2026
Investor Presentation (June 2025)49 slides · June 2025
Investor Presentation (March 2025)48 slides · March 2025
Investor Presentation (July 2024)48 slides · July 2024
Investor Presentation (June 2024)48 slides · June 2024